FDA blog aims to chronicle transparency push

FDA said it wanted to be more "transparent," more "open" about its decision-making. Already, the agency has launched a blog to detail its quest for transparency--and solicit input from the public. Enter your comments at will, but remember: no vulgar language allowed. Release

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.